CDTX News and Press, Cidara Therapeutics Inc. From 03/06/24

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serio...

2024-02-12 14:26:19 ET More on Cidara Therapeutics Cidara rallies 13% after hours on UK approval for Rezzayo Cidara, Melinta announce publication of Rezzayo data in medical journal Seeking Alpha’s Quant Rating on Cidara Therapeutics Historical earnings...

Approval triggered by positive results from ReSTORE Phase III clinical trial Payment will advance Cidara’s Cloudbreak platform for the development of drug-Fc conjugates (DFCs) SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology...

2024-01-29 17:12:24 ET More on Cidara Therapeutics, Halozyme Therapeutics, etc. Halozyme Therapeutics: A Reasonable Value In An Overvalued Market Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings C...

The UK MHRA approval follows approvals by the U.S. FDA and the European Commission Cidara is entitled to receive a milestone payment of approximately $2.8 million from Mundipharma SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology comp...

2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...

2023-12-22 09:51:52 ET DENVER, Colo., Dec. 22, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Royalty Management Holding Corp (NASDAQ: RMCO), Senti Biosciences Inc (NASDAQ: SNTI), Cidara Therapeutics Inc...

First in class, multi-specific CD73/PD-1 inhibitor DFC, exhibited robust anti-tumor activity in humanized mouse models of colorectal cancer at low doses CD73/PD-1 DFC demonstrated superior anti-tumor activity to CD73 and PD-1 monotherapies SAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE)...

Top-line data expected in Q2 2024 SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology developing therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company, along wi...

2023-12-05 11:17:43 ET More on Cidara Therapeutics Cidara Therapeutics: Reduced Risk Due To Janssen's Decision And Progress In The Oncology Pipeline Seeking Alpha’s Quant Rating on Cidara Therapeutics Historical earnings data for Cidara Therapeutics Fi...